Their most interesting finding, however, was the correlation between [89Zr]Zr-nivolumab uptake and PD-1-positive tumor-infiltrating immune cells measured by immunohistochemistry (IHC), suggesting its potential role in the non-invasive quantification of PD-1 statuses. This evidence concerns the gene PDCD1 and neoplasm.